MTNR1A and prostate carcinoma: When androgen-responsive prostate cancer LNCaP cells were treated with the analog of melatonin, 2-[125I]-melatonin, which is also a high-affinity MT1 agonist, cell proliferation was dramatically inhibited [277,280].